Comparative analysis of affected and unaffected areas of systemic sclerosis skin biopsies by high-throughput proteomic approaches.

Biomarkers Human Mass spectrometry Proteomics Rheumatology Scleroderma Skin biopsy Systemic sclerosis

Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
07 05 2020
Historique:
received: 14 01 2020
accepted: 23 04 2020
entrez: 9 5 2020
pubmed: 10 5 2020
medline: 17 6 2021
Statut: epublish

Résumé

Pathogenesis and aetiology of systemic sclerosis (SSc) are currently unclear, thus rendering disease prognosis, diagnosis and treatment challenging. The aim of this study was to use paired skin biopsy samples from affected and unaffected areas of the same patient, in order to compare the proteomes and identify biomarkers and pathways which are associated with SSc pathogenesis. Biopsies were obtained from affected and unaffected skin areas of SSc patients. Samples were cryo-pulverised and proteins were extracted and analysed using mass spectrometry (MS) discovery analysis. Differentially expressed proteins were revealed after analysis with the Progenesis QIp software. Pathway analysis was performed using the Enrichr Web server. Using specific criteria, fifteen proteins were selected for further validation with targeted-MS analysis. Proteomic analysis led to the identification and quantification of approximately 2000 non-redundant proteins. Statistical analysis showed that 169 of these proteins were significantly differentially expressed in affected versus unaffected tissues. Pathway analyses showed that these proteins are involved in multiple pathways that are associated with autoimmune diseases (AIDs) and fibrosis. Fifteen of these proteins were further investigated using targeted-MS approaches, and five of them were confirmed to be significantly differentially expressed in SSc affected versus unaffected skin biopsies. Using MS-based proteomics analysis of human skin biopsies from patients with SSc, we identified a number of proteins and pathways that might be involved in SSc progression and pathogenesis. Fifteen of these proteins were further validated, and results suggest that five of them may serve as potential biomarkers for SSc.

Sections du résumé

BACKGROUND
Pathogenesis and aetiology of systemic sclerosis (SSc) are currently unclear, thus rendering disease prognosis, diagnosis and treatment challenging. The aim of this study was to use paired skin biopsy samples from affected and unaffected areas of the same patient, in order to compare the proteomes and identify biomarkers and pathways which are associated with SSc pathogenesis.
METHODS
Biopsies were obtained from affected and unaffected skin areas of SSc patients. Samples were cryo-pulverised and proteins were extracted and analysed using mass spectrometry (MS) discovery analysis. Differentially expressed proteins were revealed after analysis with the Progenesis QIp software. Pathway analysis was performed using the Enrichr Web server. Using specific criteria, fifteen proteins were selected for further validation with targeted-MS analysis.
RESULTS
Proteomic analysis led to the identification and quantification of approximately 2000 non-redundant proteins. Statistical analysis showed that 169 of these proteins were significantly differentially expressed in affected versus unaffected tissues. Pathway analyses showed that these proteins are involved in multiple pathways that are associated with autoimmune diseases (AIDs) and fibrosis. Fifteen of these proteins were further investigated using targeted-MS approaches, and five of them were confirmed to be significantly differentially expressed in SSc affected versus unaffected skin biopsies.
CONCLUSION
Using MS-based proteomics analysis of human skin biopsies from patients with SSc, we identified a number of proteins and pathways that might be involved in SSc progression and pathogenesis. Fifteen of these proteins were further validated, and results suggest that five of them may serve as potential biomarkers for SSc.

Identifiants

pubmed: 32381114
doi: 10.1186/s13075-020-02196-x
pii: 10.1186/s13075-020-02196-x
pmc: PMC7206756
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107

Références

Rom J Intern Med. 2007;45(2):183-91
pubmed: 18333373
Rheumatology (Oxford). 2008 Dec;47(12):1754-60
pubmed: 18829709
J Rheumatol. 2017 Jan;44(1):40-48
pubmed: 27909082
Am J Physiol Lung Cell Mol Physiol. 2008 Oct;295(4):L603-11
pubmed: 18676875
Arthritis Res Ther. 2003;5(2):80-93
pubmed: 12718748
Arthritis Rheum. 2007 Jun;56(6):2013-7
pubmed: 17530641
PLoS One. 2017 Jul 27;12(7):e0175967
pubmed: 28750034
Arthritis Rheum. 2005 Mar;52(3):877-84
pubmed: 15751092
PLoS Genet. 2011 Jul;7(7):e1002178
pubmed: 21779181
Hum Immunol. 2017 Feb;78(2):153-165
pubmed: 27984087
PLoS One. 2011 Mar 09;6(3):e17551
pubmed: 21408076
Rheumatology (Oxford). 2019 Apr 1;58(4):708-718
pubmed: 30608617
Nat Med. 1999 Jun;5(6):694-7
pubmed: 10371509
Arthritis Res Ther. 2016 Nov 18;18(1):267
pubmed: 27863511
Biochem Biophys Res Commun. 1998 Oct 29;251(3):688-92
pubmed: 9790970
Cardiovasc Res. 2015 Jun 1;106(3):353-64
pubmed: 25750190
Exp Cell Res. 2013 Mar 10;319(5):750-60
pubmed: 23220213
Biomarkers. 2014 Aug;19(5):345-55
pubmed: 24831309
Ann Rheum Dis. 2004 May;63(5):569-74
pubmed: 15082489
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
Nucleic Acids Res. 2006;34(15):4168-80
pubmed: 16936318
Am J Med Sci. 2014 Jan;347(1):54-63
pubmed: 24366221
Front Immunol. 2015 Jun 08;6:272
pubmed: 26106387
J Rheumatol. 2001 Jul;28(7):1573-6
pubmed: 11469464
Front Immunol. 2012 Jun 18;3:160
pubmed: 22719739
Nature. 1994 Jan 27;367(6461):338-45
pubmed: 8114934
Bioinformatics. 2010 Apr 1;26(7):966-8
pubmed: 20147306
Nat Methods. 2014 Feb;11(2):167-70
pubmed: 24336358
Am J Hum Genet. 2008 Jun;82(6):1281-9
pubmed: 18499082
Proteomics. 2009 Mar;9(6):1683-95
pubmed: 19294628
Curr Opin Immunol. 1995 Feb;7(1):54-64
pubmed: 7772283
Arthritis Res Ther. 2006;8(4):R115
pubmed: 16859528
Am J Pathol. 2010 Oct;177(4):1638-46
pubmed: 20724591

Auteurs

Paraskevi Chairta (P)

Cyprus School of Molecular Medicine, 6 Iroon Avenue, 2371, Nicosia, Cyprus.
Neurogenetics Department, Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371, Nicosia, Cyprus.

Paschalis Nicolaou (P)

Cyprus School of Molecular Medicine, 6 Iroon Avenue, 2371, Nicosia, Cyprus.
Neurogenetics Department, Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371, Nicosia, Cyprus.

Kleitos Sokratous (K)

Cyprus School of Molecular Medicine, 6 Iroon Avenue, 2371, Nicosia, Cyprus.
Bioinformatics ERA Chair, Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371, Nicosia, Cyprus.
Present Address: OMass Therapeutics, The Schrödinger Building, Heatley Road, The Oxford Science Park, Oxford, OX4 4GE, UK.

Christine Galant (C)

Department of Pathology, Université catholique de Louvain, Bruxelles, Belgium.

Frédéric Houssiau (F)

Rheumatology Department, Cliniques Universitaires Saint-Luc, Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Université catholique de Louvain, Bruxelles, Belgium.

Anastasis Oulas (A)

Cyprus School of Molecular Medicine, 6 Iroon Avenue, 2371, Nicosia, Cyprus.
Bioinformatics ERA Chair, Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371, Nicosia, Cyprus.

George M Spyrou (GM)

Cyprus School of Molecular Medicine, 6 Iroon Avenue, 2371, Nicosia, Cyprus.
Bioinformatics ERA Chair, Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371, Nicosia, Cyprus.

Marta E Alarcon-Riquelme (ME)

Area of Medical Genomics, Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENyO), Parque Tenológico de la Salud Fundación (PTS) Granada, Spain; Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, USA.

Bernard R Lauwerys (BR)

Department of Pathology, Université catholique de Louvain, Bruxelles, Belgium.

Kyproula Christodoulou (K)

Cyprus School of Molecular Medicine, 6 Iroon Avenue, 2371, Nicosia, Cyprus. roula@cing.ac.cy.
Neurogenetics Department, Cyprus Institute of Neurology & Genetics, 6 Iroon Avenue, 2371, Nicosia, Cyprus. roula@cing.ac.cy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH